{
    "Clinical Trial ID": "NCT01385137",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I (Omega-3-fatty Acid)",
        "  Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity",
        "INTERVENTION 2: ",
        "  Arm II (Placebo)",
        "  Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed primary invasive adenocarcinoma of the breast",
        "  Stage I, II, or IIIA disease",
        "  No metastatic disease",
        "  Must have undergone modified radical mastectomy or breast-sparing surgery and recovered",
        "  Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+)",
        "  Currently taking a third-generation aromatase inhibitor (AI) [e.g., anastrozole (Arimidex\u00ae), letrozole (Femara\u00ae), or exemestane (Aromasin\u00ae)] for  90 days prior to registration with plans to continue for  180 days after registration",
        "  Must have completed the S092 Brief Pain Inventory (BPI)-Short Form within the past 14 days, and must have a worst pain/stiffness of  5 on the BPI (item #2) that has started or increased with AI therapy",
        "  PATIENT CHARACTERISTICS:",
        "  Postmenopausal",
        "  Zubrod performance status 0-2",
        "  Willing to submit blood for serum-free estradiol, total estradiol, serum inflammatory markers (IL6, TNF-\u03b1, CRP), DHA and EPA, lipid profile (LDL, HDL, triglycerides), and DNA analysis (CYP19A1)",
        "  Able to complete study questionnaires in English",
        "  At least 5 years since other malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast or adequately treated stage I or II cancer from which the patient is currently in complete remission",
        "  Patients must not have a known allergy to soy, given that the placebo is suspended in soybean oil",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  At least 3 months since prior omega-3 fatty acid supplements and must agree to refrain from omega-3-fatty acid supplements from sources outside of this study",
        "  More than 28 days since prior investigational agents",
        "  No other medical therapy, alternative therapy, or physical therapy for joint pain/stiffness within the past 30 days",
        "  Patients must not be on anticoagulation medication (i.e., heparin/warfarin) because of increased risk of bleeding within 28 days prior to registration",
        "  Patients must not have a history of bone fracture or surgery of the afflicted knees and/or hands within 6 months prior to registration",
        "  Patients must not be on narcotics within 14 days of registration",
        "  Patients may have received corticosteroid treatment; however, the following criteria apply:",
        "  Patients must not have received oral or intramuscular corticosteroids within the 28 days prior to registration",
        "  Patients must not have received intra-articular steroids to the study, or any other, joint within 28 days prior to registration",
        "  Patients must not have received topical analgesics (e.g., capsaicin preparations) to the study joint or any other analgesics (e.g., opiates, tramadol; with the exception of nonsteroidal antiinflammatory drugs (NSAIDs) and acetaminophen) within 14 days prior to registration"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Week 12 Brief Pain Inventory (BPI) Worst Pain/Stiffness Score",
        "  Linear regression model-adjusted week 12 mean score by treatment group.",
        "  Purpose: To assess the severity of pain Population: Patients with pain from chronic diseases or conditions such as cancer, osteoarthritis and low back pain, or with pain from acute conditions such as postoperative pain Responsiveness: Responds to both behavioral and pharmacological pain interventions Method: Self-report or interview Scoring: Higher scores indicate more pain Range: 0-10",
        "  Time frame: 12 weeks post-registration",
        "Results 1: ",
        "  Arm/Group Title: Arm I (Omega-3-fatty Acid)",
        "  Arm/Group Description: Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity",
        "  Overall Number of Participants Analyzed: 102",
        "  Mean (95% Confidence Interval)",
        "  Unit of Measure: BPI score  5.3        (4.68 to 5.91)",
        "Results 2: ",
        "  Arm/Group Title: Arm II (Placebo)",
        "  Arm/Group Description: Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity",
        "  Overall Number of Participants Analyzed: 107",
        "  Mean (95% Confidence Interval)",
        "  Unit of Measure: BPI score  5.47        (4.86 to 6.09)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/117 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/124 (0.00%)"
    ]
}